ISRCTN17465143 https://doi.org/10.1186/ISRCTN17465143

Ultra low dose anticoagulation in atrial fibrillation

Submission date 23/01/2004	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 23/01/2004	**Overall study status** Completed	
Last Edited 30/08/2012	**Condition category** Circulatory System	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Gareth Beevers

Contact details
University Department of Medicine
City Hospital
Dudley Rd
Birmingham
United Kingdom
B18 7QH
+44 (0)121 507 5080

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
MC7

Study information

Scientific Title

Study objectives
Previous studies have demonstrated increased markers of thrombogenesis in patients with atrial fibrillation (AF), suggesting the presence of a hypercoaguable or prothromobotic state. The objective of this study was to determine the effects of introducing ultra-low-dose warfarin (1 mg), conventional warfarin, and aspirin (300 mg) therapy on thrombogenesis and platelet activation in AF.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Heart disease

Interventions
3 treatment arms:
1. Ultra-low-dose warfarin (1 mg)
2. Conventional warfarin
3. Aspirin (300 mg)

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Warfarin, aspirin

Primary outcome measure
Platelet activation

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/04/1994

Completion date
01/04/1996

Eligibility

Key inclusion criteria
Patients with atrial fibrillation

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Does not match inclusion criteria

Date of first enrolment
01/04/1994

Date of final enrolment
01/04/1996

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
University Department of Medicine
Birmingham
United Kingdom
B18 7QH

Sponsor information

Organisation
Record Provided by the NHS R&D 'Time-Limited' National Programme Register - Department of Health (UK)

Sponsor details
The Department of Health
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
http://www.doh.gov.uk

Funder(s)

Funder type
Government

Funder Name
NHS Cardiovascular Disease and Stroke National Research and Development Programme (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/1996		Yes	No